Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2332544rdf:typepubmed:Citationlld:pubmed
pubmed-article:2332544lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:2332544lifeskim:mentionsumls-concept:C0019010lld:lifeskim
pubmed-article:2332544lifeskim:mentionsumls-concept:C0002697lld:lifeskim
pubmed-article:2332544lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2332544lifeskim:mentionsumls-concept:C0524727lld:lifeskim
pubmed-article:2332544pubmed:issue2lld:pubmed
pubmed-article:2332544pubmed:dateCreated1990-6-7lld:pubmed
pubmed-article:2332544pubmed:abstractTextThe hemodynamic effects of amrinone were assessed in seven children following cardiac surgery. Amrinone was administered as a bolus of 1 mg kg-1 body wt., followed by continuous infusion at 10 micrograms kg-1 min-1 for 1 h and two stepwise increases to 20 and 40 micrograms kg-1 min-1 for 30 min each. Hemodynamic data were obtained and plasma concentrations of amrinone measured 1 h after the bolus dose and immediately before each increment of the infusion rate. Amrinone levels ranged from 0.7 to 2.3 mg l-1. Administration of amrinone lowered systemic vascular resistance from 20.0 +/- 4.3 to 16.5 +/- 4.6 mmHg l-1 min-1 m-2 (p less than 0.05) and reduced mean arterial pressure from 71.7 +/- 9.5 to 62.6 +/- 13.5 mmHg (p less than 0.05) at the highest infusion rate, confirming the known vasodilative effect of the drug. However, these effects did not result in a statistically significant increase in stroke volume (35.0 +/- 7.5 to 35.5 +/- 7.0 ml m-2, NS) or cardiac index (3.10 +/- 0.50 to 3.20 +/- 0.40 l min-1 m-2). One additional patient, in whom a higher loading dose was tried in order to achieve a higher plasma concentration, developed systemic hypotension. A correlation was established between the plasma concentrations of amrinone and the percentage decrease in systemic resistance (r = 0.70, p less than 0.05). These results suggest that in children after open heart surgery, amrinone acts primarily as a systemic vasodilator, with questionable inotropic effect. Accordingly, its use should be restricted to children with severe cardiac failure and documented highly elevated afterload.lld:pubmed
pubmed-article:2332544pubmed:languageenglld:pubmed
pubmed-article:2332544pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2332544pubmed:citationSubsetIMlld:pubmed
pubmed-article:2332544pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2332544pubmed:statusMEDLINElld:pubmed
pubmed-article:2332544pubmed:issn0342-4642lld:pubmed
pubmed-article:2332544pubmed:authorpubmed-author:RougeJ CJClld:pubmed
pubmed-article:2332544pubmed:authorpubmed-author:FriedliBBlld:pubmed
pubmed-article:2332544pubmed:authorpubmed-author:BernerMMlld:pubmed
pubmed-article:2332544pubmed:authorpubmed-author:JaccardCClld:pubmed
pubmed-article:2332544pubmed:authorpubmed-author:OberhansliIIlld:pubmed
pubmed-article:2332544pubmed:issnTypePrintlld:pubmed
pubmed-article:2332544pubmed:volume16lld:pubmed
pubmed-article:2332544pubmed:ownerNLMlld:pubmed
pubmed-article:2332544pubmed:authorsCompleteYlld:pubmed
pubmed-article:2332544pubmed:pagination85-8lld:pubmed
pubmed-article:2332544pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:2332544pubmed:meshHeadingpubmed-meshheading:2332544-...lld:pubmed
pubmed-article:2332544pubmed:meshHeadingpubmed-meshheading:2332544-...lld:pubmed
pubmed-article:2332544pubmed:meshHeadingpubmed-meshheading:2332544-...lld:pubmed
pubmed-article:2332544pubmed:meshHeadingpubmed-meshheading:2332544-...lld:pubmed
pubmed-article:2332544pubmed:meshHeadingpubmed-meshheading:2332544-...lld:pubmed
pubmed-article:2332544pubmed:meshHeadingpubmed-meshheading:2332544-...lld:pubmed
pubmed-article:2332544pubmed:meshHeadingpubmed-meshheading:2332544-...lld:pubmed
pubmed-article:2332544pubmed:meshHeadingpubmed-meshheading:2332544-...lld:pubmed
pubmed-article:2332544pubmed:meshHeadingpubmed-meshheading:2332544-...lld:pubmed
pubmed-article:2332544pubmed:meshHeadingpubmed-meshheading:2332544-...lld:pubmed
pubmed-article:2332544pubmed:meshHeadingpubmed-meshheading:2332544-...lld:pubmed
pubmed-article:2332544pubmed:meshHeadingpubmed-meshheading:2332544-...lld:pubmed
pubmed-article:2332544pubmed:year1990lld:pubmed
pubmed-article:2332544pubmed:articleTitleHemodynamic effects of amrinone in children after cardiac surgery.lld:pubmed
pubmed-article:2332544pubmed:affiliationClinique Universitaire de Pediatrie, Geneva, Switzerland.lld:pubmed
pubmed-article:2332544pubmed:publicationTypeJournal Articlelld:pubmed